Google
ABCL — ABCELLERA BIOLOGICS INC (Healthcare >> Biotechnology)
ABCL FAQ
What is ABCL's ROE?
ABCELLERA BIOLOGICS INC reports a Return on Equity (ROE) of -15.35%.
What is ABCL's dividend yield?
ABCELLERA BIOLOGICS INC offers a dividend yield of 0.00%.
What is ABCL's Deepscope Quality Score?
Deepscope rates ABCL's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy ABCL?
Deepscope's AI Timing Score for ABCL is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does ABCL belong to?
ABCELLERA BIOLOGICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 5.62
Price
-0.75
(-11.77%)
Day Change
|
|
|---|
ABCL, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
ROAがROEに比べて低い
ROAの伸びが低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 5.62 |
| PBV / Sector |
2.07 / 4.63
|
| Earning Per Share | -0.42 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
47.16 M
GREAT
|
| Average 1W Daily Value |
51.14 M
|
| Timing Factors |
|
71% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
56% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-06 09:08:25 |
| Symbol | ABCL |
| Name | ABCELLERA BIOLOGICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 305.38 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,945.24 / 8,857.28 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 150 W 4th Avenue, Vancouver, BC, Canada, V5Y 1G6
Phone: 604 559 9005
Website: https://www.abcellera.com
Employees: 562
Sector: Healthcare >> Biotechnology
Description: AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
